{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T22:25:19Z","timestamp":1787955919097,"version":"build-2784847793"},"reference-count":25,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"NHLBI","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"NCATS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.jtha.2024.07.005","type":"journal-article","created":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T02:51:13Z","timestamp":1721184673000},"page":"2935-2938","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Understanding the difference between type I and type II antiprothrombin antibodies and their effect on activated protein C resistance"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2309-7100","authenticated-orcid":false,"given":"Nicola","family":"Pozzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Pontara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0710-2520","authenticated-orcid":false,"given":"Suresh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorio","family":"Pengo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2024.07.005_bib1","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1002\/1529-0131(200009)43:9<1982::AID-ANR9>3.0.CO;2-2","article-title":"Association of autoantibodies against the phosphatidylserine-prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant","volume":"43","author":"Atsumi","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jtha.2024.07.005_bib2","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1160\/TH13-06-0509","article-title":"Anti-prothrombin (aPT) and anti-phosphatidylserine\/prothrombin (aPS\/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome. A systematic review","volume":"111","author":"Sciascia","year":"2014","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.07.005_bib3","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1056\/NEJMra1705454","article-title":"Diagnosis and management of the antiphospholipid syndrome","volume":"378","author":"Garcia","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.07.005_bib4","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrrheum.2011.52","article-title":"Pathogenesis of antiphospholipid syndrome: understanding the antibodies","volume":"7","author":"Meroni","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jtha.2024.07.005_bib5","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41584-024-01110-y","article-title":"Rethinking antiphospholipid syndrome to guide future management and research","volume":"20","author":"Knight","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jtha.2024.07.005_bib6","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1182\/blood.V81.10.2618.2618","article-title":"Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism?","volume":"81","author":"Oosting","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.07.005_bib7","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1177\/096120339400300405","article-title":"Protein C pathway, antiphospholipid antibodies, and thrombosis","volume":"3","author":"de Groot","year":"1994","journal-title":"Lupus"},{"key":"10.1016\/j.jtha.2024.07.005_bib8","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1006\/jaut.2000.0407","article-title":"Antiphospholipid antibodies and the protein C pathway","volume":"15","author":"Esmon","year":"2000","journal-title":"J\u00a0Autoimmun"},{"key":"10.1016\/j.jtha.2024.07.005_bib9","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1177\/0961203309360841","article-title":"Antiphospholipid antibodies and the protein C pathway","volume":"19","author":"Urbanus","year":"2010","journal-title":"Lupus"},{"key":"10.1016\/j.jtha.2024.07.005_bib10","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1055\/s-0041-1742083","article-title":"Interaction between antiphospholipid antibodies and protein C anticoagulant pathway: a narrative review","volume":"48","author":"Pengo","year":"2022","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.jtha.2024.07.005_bib11","doi-asserted-by":"crossref","first-page":"18107","DOI":"10.1074\/jbc.M116.738310","article-title":"Structural architecture of prothrombin in solution revealed by single molecule spectroscopy","volume":"291","author":"Pozzi","year":"2016","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jtha.2024.07.005_bib12","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1038\/s41598-018-21304-1","article-title":"Structure of prothrombin in the closed form reveals new details on the mechanism of activation","volume":"8","author":"Chinnaraj","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.jtha.2024.07.005_bib13","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3389\/fmed.2018.00281","article-title":"Structure of coagulation factor II: molecular mechanism of thrombin generation and development of next-generation anticoagulants","volume":"5","author":"Chinnaraj","year":"2018","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jtha.2024.07.005_bib14","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1182\/bloodadvances.2019030932","article-title":"Discovery and characterization of 2 novel subpopulations of aPS\/PT antibodies in patients at high risk of thrombosis","volume":"3","author":"Chinnaraj","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2024.07.005_bib15","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1182\/blood.2023022942","article-title":"Cryo-EM structure and functional basis of prothrombin recognition by a type I antiprothrombin antiphospholipid antibody","volume":"143","author":"Kumar","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.07.005_bib16","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1021\/bi030167f","article-title":"Lupus-derived antiprothrombin autoantibodies from a V gene phage display library are specific for the kringle 2 domain of prothrombin","volume":"43","author":"Le","year":"2004","journal-title":"Biochemistry"},{"key":"10.1016\/j.jtha.2024.07.005_bib17","doi-asserted-by":"crossref","first-page":"4173","DOI":"10.1182\/blood.V88.11.4173.bloodjournal88114173","article-title":"Mechanism and effects of the binding of lupus anticoagulant IgG and prothrombin to surface phospholipid","volume":"88","author":"Rao","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.07.005_bib18","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/ajcp\/107.2.197","article-title":"A\u00a0new method for characterization and epitope determination of a lupus anticoagulant-associated neutralizing antiprothrombin antibody","volume":"107","author":"Cote","year":"1997","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.jtha.2024.07.005_bib19","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/jth.15199","article-title":"Insight into the hypercoagulable state of high-risk thrombotic APS patients: contribution of abeta2GPI and aPS\/PT antibodies","volume":"19","author":"Pontara","year":"2021","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.07.005_bib20","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1016\/j.jtha.2023.06.033","article-title":"Close link between antiphosphatidylserine\/prothrombin antibodies, lupus anticoagulant, and activated protein C resistance in tetra antiphospholipid antibody-positive subjects","volume":"21","author":"Pontara","year":"2023","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.07.005_bib21","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s11926-024-01140-1","article-title":"Thrombin generation assay in antiphospholipid antibodies positive subjects as a personalized thrombotic risk assessment: state of the art and perspectives","volume":"26","author":"Foret","year":"2024","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.jtha.2024.07.005_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.741589","article-title":"A\u00a0novel ELISA assay for the detection of anti-prothrombin antibodies in antiphospholipid syndrome patients at high risk of thrombosis","volume":"12","author":"Chinnaraj","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtha.2024.07.005_bib23","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/978-1-0716-3175-1_20","article-title":"Laboratory testing for non-criteria antiphospholipid antibodies: anti-phosphatidylserine\/prothrombin antibodies (aPS\/PT)","volume":"2663","author":"Devreese","year":"2023","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.jtha.2024.07.005_bib24","doi-asserted-by":"crossref","first-page":"SI64","DOI":"10.1093\/rheumatology\/kead632","article-title":"Viewpoint: the value of non-criteria antiphospholipid antibodies","volume":"63","author":"de Laat","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jtha.2024.07.005_bib25","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1111\/jth.15320","article-title":"Antiprothrombin antibodies induce platelet activation: a possible explanation for anti-FXa therapy failure in patients with antiphospholipid syndrome?","volume":"19","author":"Chayoua","year":"2021","journal-title":"J\u00a0Thromb Haemost"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783624004227?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783624004227?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T20:46:04Z","timestamp":1759351564000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783624004227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S1538783624004227"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2024.07.005","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Understanding the difference between type I and type II antiprothrombin antibodies and their effect on activated protein C resistance","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2024.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}